Local 12, WCPO highlight brain tumor vaccine trial
Local television stations Local 12 and WCPO recently highlighted the Imvax trial that will test a personalized immunotherapy approach designed to work similarly to a vaccine by training the immune system to fight glioblastomas, a deadly brain tumor.
The University of Cincinnati is a study site for the new Phase 2b clinical trial, and Soma Sengupta, MD, PhD, is the site principal investigator.
In the trial, glioblastoma patients will have their tumors removed, and then their tumor cells will be combined with a novel drug to create a personalized vaccine. The combination is then inserted into the patients' abdomens, allowing the immune system to train to fight the tumor cells.
"The patient is making their own antibodies, and their own immune system is working to try and beat this cancer," Sengupta told Local 12.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Bono, Chris Tucker Visit UC To Discuss Africa
December 5, 2002
U2's Bono and comedian-actor Chris Tucker led a delegation from the DATA organization who came to UC to talk about potentially catastrophic problems in Africa.
New Year's Help for Those Looking to Kick the Habit
December 20, 2002
Quitting smoking consistently ranks among the top three resolutions made by New Year's resolvers each year.
E-BRIEF: Let's Toast to a Healthier 2003
January 8, 2003
The New Year often means a new health kick: Vows to tone up and trim down, and maybe going to the doctor and getting ourselves as regularly "maintenanced" as we do our cars. So, this week's University of Cincinnati e-briefing examines the health concerns of the young and old, and what you should be doing to preserve your good health.